ECSP22003596A - NMDA RECEPTOR MODULATORS - Google Patents

NMDA RECEPTOR MODULATORS

Info

Publication number
ECSP22003596A
ECSP22003596A ECSENADI20223596A ECDI202203596A ECSP22003596A EC SP22003596 A ECSP22003596 A EC SP22003596A EC SENADI20223596 A ECSENADI20223596 A EC SENADI20223596A EC DI202203596 A ECDI202203596 A EC DI202203596A EC SP22003596 A ECSP22003596 A EC SP22003596A
Authority
EC
Ecuador
Prior art keywords
nmda receptor
receptor modulators
compounds
depression
disorders
Prior art date
Application number
ECSENADI20223596A
Other languages
Spanish (es)
Inventor
John Kilburn
Mauro Marigo
Laurent David
Erhad Ascic
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of ECSP22003596A publication Critical patent/ECSP22003596A/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B62—LAND VEHICLES FOR TRAVELLING OTHERWISE THAN ON RAILS
    • B62D—MOTOR VEHICLES; TRAILERS
    • B62D15/00—Steering not otherwise provided for
    • B62D15/02—Steering position indicators ; Steering position determination; Steering aids
    • B62D15/027—Parking aids, e.g. instruction means
    • B62D15/0285—Parking performed automatically
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60W—CONJOINT CONTROL OF VEHICLE SUB-UNITS OF DIFFERENT TYPE OR DIFFERENT FUNCTION; CONTROL SYSTEMS SPECIALLY ADAPTED FOR HYBRID VEHICLES; ROAD VEHICLE DRIVE CONTROL SYSTEMS FOR PURPOSES NOT RELATED TO THE CONTROL OF A PARTICULAR SUB-UNIT
    • B60W30/00—Purposes of road vehicle drive control systems not related to the control of a particular sub-unit, e.g. of systems using conjoint control of vehicle sub-units, or advanced driver assistance systems for ensuring comfort, stability and safety or drive control systems for propelling or retarding the vehicle
    • B60W30/06—Automatic manoeuvring for parking
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60W—CONJOINT CONTROL OF VEHICLE SUB-UNITS OF DIFFERENT TYPE OR DIFFERENT FUNCTION; CONTROL SYSTEMS SPECIALLY ADAPTED FOR HYBRID VEHICLES; ROAD VEHICLE DRIVE CONTROL SYSTEMS FOR PURPOSES NOT RELATED TO THE CONTROL OF A PARTICULAR SUB-UNIT
    • B60W60/00—Drive control systems specially adapted for autonomous road vehicles
    • B60W60/001—Planning or execution of driving tasks
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60W—CONJOINT CONTROL OF VEHICLE SUB-UNITS OF DIFFERENT TYPE OR DIFFERENT FUNCTION; CONTROL SYSTEMS SPECIALLY ADAPTED FOR HYBRID VEHICLES; ROAD VEHICLE DRIVE CONTROL SYSTEMS FOR PURPOSES NOT RELATED TO THE CONTROL OF A PARTICULAR SUB-UNIT
    • B60W2510/00—Input parameters relating to a particular sub-units
    • B60W2510/20—Steering systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Transportation (AREA)
  • Mechanical Engineering (AREA)
  • Automation & Control Theory (AREA)
  • Epidemiology (AREA)
  • Combustion & Propulsion (AREA)
  • Human Computer Interaction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a nuevos moduladores del receptor de NMDA. Aspectos separados de las invenciones se refieren a composiciones farmacéuticas que comprenden dichos compuestos y a usos de los compuestos para tratar trastornos neurológicos o trastornos neuropsiquiátricos tales como la depresión.The present invention relates to new NMDA receptor modulators. Separate aspects of the inventions relate to pharmaceutical compositions comprising said compounds and to uses of the compounds for treating neurological disorders or neuropsychiatric disorders such as depression.

ECSENADI20223596A 2019-07-03 2022-01-17 NMDA RECEPTOR MODULATORS ECSP22003596A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201900821 2019-07-03

Publications (1)

Publication Number Publication Date
ECSP22003596A true ECSP22003596A (en) 2022-02-25

Family

ID=74065626

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20223596A ECSP22003596A (en) 2019-07-03 2022-01-17 NMDA RECEPTOR MODULATORS

Country Status (20)

Country Link
US (1) US11466027B2 (en)
EP (1) EP3994141A1 (en)
JP (1) JP2022539197A (en)
KR (1) KR20220029568A (en)
CN (1) CN114008054A (en)
AR (1) AR119340A1 (en)
AU (1) AU2020299992A1 (en)
BR (1) BR112021003928A2 (en)
CA (1) CA3144304A1 (en)
CL (1) CL2021003557A1 (en)
CO (1) CO2021017142A2 (en)
CR (1) CR20210662A (en)
EC (1) ECSP22003596A (en)
IL (1) IL289575A (en)
JO (1) JOP20210331A1 (en)
MA (1) MA56451A (en)
MX (1) MX2021015742A (en)
PE (1) PE20220137A1 (en)
TW (1) TW202116779A (en)
WO (1) WO2021001423A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11358971B2 (en) 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026700A (en) 1989-05-16 1991-06-25 Merrell Dow Pharmaceuticals Certain quinolines and thienopyridines as excitatory amino acid antagonists
US5252581A (en) 1992-07-20 1993-10-12 Hoechst-Roussel Pharmaceuticals Inc. Substituted aminothienopyridines, pharmaceutical composition and use
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
DE69434889D1 (en) 1994-02-08 2007-01-11 Nps Pharma Inc Compounds acting on a new site of receptor-dependent calcium channels for the treatment of neurological disorders
WO1997046511A1 (en) 1996-06-07 1997-12-11 Nps Pharmaceuticals, Inc. Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
WO1998056752A1 (en) 1997-06-11 1998-12-17 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
CL2003002287A1 (en) 2002-11-25 2005-01-14 Wyeth Corp COMPOUNDS DERIVED FROM TIENO [3,2-b] -PIRIDINA-6-CARBONITRILOS AND TIENEO [2,3-b] -PIRIDINA-5-CARBONITRILS, PHARMACEUTICAL COMPOSITION, PROCEDURE OF PREPARATION AND INTERMEDIARY COMPOUNDS, AND THEIR USE IN THE TREATMENT OF CANCER, APOPLEJIA, OSTEOPOROSIS
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
CA2789474A1 (en) * 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
US11358971B2 (en) 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor

Also Published As

Publication number Publication date
BR112021003928A2 (en) 2021-05-18
AU2020299992A1 (en) 2022-02-24
CL2021003557A1 (en) 2022-08-19
CA3144304A1 (en) 2021-01-07
TW202116779A (en) 2021-05-01
US20210002292A1 (en) 2021-01-07
WO2021001423A1 (en) 2021-01-07
PE20220137A1 (en) 2022-01-27
MA56451A (en) 2022-05-11
JOP20210331A1 (en) 2023-01-30
IL289575A (en) 2022-03-01
MX2021015742A (en) 2022-01-27
CO2021017142A2 (en) 2022-01-17
US11466027B2 (en) 2022-10-11
CR20210662A (en) 2022-03-02
EP3994141A1 (en) 2022-05-11
AR119340A1 (en) 2021-12-09
JP2022539197A (en) 2022-09-07
CN114008054A (en) 2022-02-01
KR20220029568A (en) 2022-03-08

Similar Documents

Publication Publication Date Title
SV2016005311A (en) COMPOUNDS AND COMPOSITIONS AS AGENTS OF THE TOLL TYPE 7 RECEIVER
CL2020000422A1 (en) Compositions of glp-1 and their uses.
CL2018003265A1 (en) Modular of the spiro-lactam n-methyl-d-aspartate receptor and uses thereof.
DOP2018000204A (en) NICOTINIC ACETILCOLINE RECEPTORS ALOSTERIC MODULATORS
UY36126A (en) ? 6,8-DIOXABICICLO COMPOUNDS [3.2.1] OCTANO-2,3-DIOL REPLACED AS ADDRESS AGENTS TO ASGPR ?.
DOP2017000117A (en) 2-AMINO-6- (DIFLUOROMETIL) - 5,5-DIFLUORO-6-PHENYL-3,4,5,6-TETRAHYDROPIRIDINES AS INHIBITORS OF BACE1
CL2015002121A1 (en) Modular spiro-lactam nmda receptors and their uses.
CR20190392A (en) Aryl hydrocarbon receptor (ahr) modulator compounds
DOP2014000230A (en) AGENTS TO TREAT DISORDERS THAT INVOLVE THE MODULATION OF RIANODINE RECEPTORS
CL2022000201A1 (en) akr1c3-dependent tricyclic inhibitors of kars
CO2019012767A2 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compound
CR20190393A (en) Aryl hydrocarbon receptor (ahr) modulator compounds
CL2018001210A1 (en) Novel cryptophycin compounds and conjugated products, their preparation and therapeutic use.
CO2021014008A2 (en) Pharmaceutical Compounds for the Treatment of Complement-Mediated Disorders
CL2020001140A1 (en) Spirocyclic compounds as modulators of the x-farnesoid receptor.
CL2021002357A1 (en) Fused and Related Bicyclic Piperidinyl Compounds as Modulators of the c5a Receptor
UY37729A (en) NEW COMPOUNDS THAT INHIBIT THE ACTIVITY OF Nav1.7
CL2015002545A1 (en) New phosphodiesterase inhibitor compounds of type 10a.
CL2021000930A1 (en) Novel Pyridazines
ECSP22003596A (en) NMDA RECEPTOR MODULATORS
CL2021003534A1 (en) Prodrugs of nmda receptor modulators.
CO2021001174A2 (en) Ckd8 / 19 inhibitors
CR20170195A (en) ESPIRO-TIAZOLONAS
DOP2022000026A (en) ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS
UY38217A (en) DERIVATIVES OF 1-IMIDAZOTIADIAZOL-2H-PIRROL-5-ONA